Regorafenib Tablets (Reodixin®) – 40?mg
$1.00
Regorafenib (Reodixin®) is an oral multi-kinase inhibitor targeting angiogenesis, proliferation, metastasis, and tumor immunity. FDA-approved for several advanced solid tumors. Here offered as 40?mg tablets in a 28-count bottle—strictly for laboratory research use only
描述
Regorafenib Tablets Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Regorafenib Tablets (Reodixin®) |
| Strength | 40?mg per tablet |
| Quantity | 28 tablets per bottle |
| Dosage Form | Oral film-coated tablet |
| Approval No. | China NMPA H20243057 |
| Product Code | 86900647000343 |
| Manufacturer | Shanghai Chuannuo Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research use only—Not for human or veterinary use |
Overview & Mechanism
Regorafenib is a potent multi-kinase inhibitor that targets RTKs critical to tumor growth: VEGFR1/2/3, TIE2, PDGFR, FGFR, KIT, RET, RAF1, BRAF, and CSF1R. It suppresses angiogenesis, proliferation, metastasis, and modulates the tumor immune microenvironment sciencedirect.comoncologynewscentral.com+5stivarga.com+5stivargahcp.com+5de.wikipedia.org+2pmc.ncbi.nlm.nih.gov+2stivargahcp.com+2.
Research & Clinical Background
-
FDA-approved for metastatic colorectal cancer, GIST, and hepatocellular carcinoma
-
Shown to extend median overall survival in metastatic colorectal cancer (CORRECT, CONCUR trials) by ~1.4–2.5 months
-
Demonstrates broad signaling pathway inhibition, including anti-angiogenic and immunomodulatory effects
Research Applications
Ideal for use in:
-
Angiogenesis and TME modeling
-
Kinase signaling pathway assays
-
Drug resistance and combination studies
-
Metastasis and proliferation models
-
Pharmacodynamic and bioactivity profiling
?? Research-Use Disclaimer
This product is provided strictly for laboratory research and development use only.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 26 × 28 × 26 厘米 |
Regorafenib Tablets (Reodixin®) – 40?mg 有 1 个评价
相关产品
-
Reduced Glutathione Injection 0.6?g × 10 Vials – Ruiyang | Price comparison
Ruiyang Reduced Glutathione Injection (0.6?g per vial × 10) by Ruiyang Pharmaceutical Co., Ltd. Ideal for antioxidant, detoxification, and hepatic-protection research in metabolic and oxidative stress studies.
?? For laboratory research use only – Not for human consumption or therapeutic use. $2.00 -
Elranatamab Injection 76?mg/1.9?mL/Freeze-dried powder
Elranatamab (ELREXFIO®) is a BCMA-CD3 bispecific antibody used in multiple myeloma research. Supplied as a 76?mg/1.9?mL single-dose vial, manufactured by Pfizer. Approved by FDA (Aug?2023) and EMA (Dec?2023). Ideal for oncology, immunotherapy, and T?cell engager studies.
$1.00
?? For laboratory research use only – Not for human consumption or therapeutic use. -
Temozolomide Capsules 100?mg × 5 – ChuanNuo (MySean) | Research Grade Glioblastoma Drug
Temozolomide 100?mg capsules, 5?count box, produced by Shanghai ChuanNuo Pharmaceuticals Co., Ltd., approved under NMPA H20234716. A key alkylating agent for glioblastoma and astrocytoma research—ideal for preclinical oncology models.
?? For laboratory research or analytical use only – Not for human consumption or therapeutic use. $1.00 -
Fulzerasib Tablets (Dupert®) – 150?mg × 112 Tablets per Box Price comparison
Fulzerasib (Dupert®) is an orally active KRAS G12C inhibitor, conditionally approved in China for advanced non–small-cell lung cancer (NSCLC) with KRAS G12C mutation. Manufactured by CindaBio, NMPA approved under H20240035 (drug code: 86985200000015). Strictly for laboratory research use only—NOT for clinical or human consumption. $1.00
yaser –
Das Paket ist angekommen, danke